BACKGROUND Mean mitral gradient (MMG) increases after percutaneous edge-to-edge repair of mitral regurgitation (MR). Near complete reduction of MR has been associated with improved outcomes but may result in an elevated MMG. However, it is not known whether an elevated post-procedural MMG is associated with all-cause mortality.
METHODS Patients (pts) who underwent percutaneous repair of MR between April 2009 and May 2014 with the MitraClip device (Abbott Vascular, Santa Clara, CA) were included. An elevated gradient was defined as a MMG !5 mmHg on transthoracic echocardiogram prior to discharge. Survival was compared between pts with and without an elevated post-procedural MMG by Log Rank test. Univariate Cox regression analysis of all-cause mortality was performed for the predictor variables of post-procedural MMG and change in MMG. Multivariate logistic regression analysis of predictors for an elevated post-procedural MMG was performed for normal ejection fraction !60%, reduction of MR mild-or-moderate, number of clips placed, and age.
RESULTS 174 pts were included in the analysis. Mean age at percutaneous repair was 76.9 AE 12.6 yrs and 40.8% were females. Post-procedural MMG ranged from 1 to 10 mmHg. An elevated postprocedural MMG !5 mmHg occurred in 52/174 (29.9%) of pts with an average MMG of 5.9 AE 1.2 mmHg in this group. MMG was significantly lower in the remaining pts (2.7 AE 0.9 mmHg) p<0.001. Baseline MR was moderate-to-severe in 36/174 (20.7%) of pts and severe in 138/174 (79.3%) of pts and not different between the groups (p¼1.000). Number of clips used was 1.5 AE 0.5 (median 2) and not different between the groups (p¼0.144). Procedural success of reducing MR by 2 or more grades (95.4% of pts) or to less than or equal to mild-ormoderate (82.8% of pts) was not different between groups p¼0.242 and p¼0.665, respectively. Pts with an elevated post-procedural MMG had a higher increase in MMG 3.6 AE 1.5 vs. 0.9 AE 1.0 mmHg (p<0.001) after clipping. Pts with an elevated post-procedural MMG had improved survival (Log rank p¼0.036). In univariate Cox regression analysis both post-procedural MMG and change in MMG were associated with decreased all-cause mortality hazard ratio 0.839 (95% CI 0.721 -0.977) p¼0.024 and 0.830 (95% CI 0.711 -0.969) p¼0.019, respectively. On multivariate logistic regression analysis pts with normal ejection fraction !60% had an odds ratio of 2.241 (95% CI 1.125 -4.461) p¼0.022 for developing an elevated post-procedural MMG. Reduction of MR to mild-or-moderate, number of clips, and age were not significantly associated with an elevated post-procedural MMG.
CONCLUSIONS Moderate elevation of post-procedural MMG is not associated with increased mortality and may be the expression of improved hemodynamics. An increase of MMG !3 mmHg to a postprocedural MMG of 5-10 mmHg might be expected for optimal outcomes. METHODS Twelve patients with severe symptomatic mitral stenosis who underwent PTMC were included, all patients were subjected to transthoracic echocardiography assessment of severity of mitral stenosis and right ventricular systolic function before and 24h post-PTMC then at one and three months.
RESULTS Mean age was 37þ/-4,6 years, two-thirds were female, two patients (16,7%) had previous PTMC, quarter of patients were in atrial fibrillation, all patients were symptomatic. Mitral valve area increased from 1.05þ/-0.26 cm2 to 2.02þ/-0.45 cm2 (p<0.0001). Mean gradient decreased from 13.52þ/-5.09 mmHg to 5.38 þ/-3.15 mmHg (p<0.0001). There was a significant decrease in systolic pulmonary artery pressure from 38.13þ/-7,55 mmHg to 28,25þ/-4.65mmHg (p¼0.006). Pulmonary resistance measured by echocardiography using Tricuspid regurgitation Vmax / Tricuspid VTI ratio dropped from 0.140þ/-0.017 to 0.116þ/-0.015 (p¼0.023). Tricuspid annular point systolic excursion (TAPSE) increased from 21.58þ/-3.08mm to 24.25þ/-4.80mm (p¼0.029) then to 24.10þ/-5.28mm (p¼0.091) and to 24.10þ/-5.28mm (p ¼0.091). Systolic velocity (S') at lateral tricuspid annulus increased from 12.80þ/-3.76cm to 14.90þ/-3.98cm (p¼0.004) and to 14.80þ/-3.79cm (p¼0.015) then to 15.60þ/-3.92cm (p¼0.001). Tei index decreased from 0.359þ/-0.222 to 0.207þ/-0.095 (p¼0.026) and to 0.203þ/-0.089 (p¼0.024) then to 0.201þ/-0.086 (p¼0.014). Myocardial acceleration during isovolumic contraction (IVA) increased from 0.410þ/-0.106 m/s2 (p¼0.027) to 0.568þ/-0.256 m/s2 and to 0.570þ/-0.218 m/s2 (p¼0.010) then to 0.615þ/-0.231 m/s2 (p¼0.003) respectively at baseline, 24h, one month and three months after PTMC. There was no significant fraction area change and dp/dt ratio of the right ventricle immediately and at mid term after PTMC.
CONCLUSIONS We suggest that there is an immediate improvement of right ventricular systolic function after PTMC that is maintained at mid term follow-up. Also the fact that this tendency was confirmed by using echocardiographic parameters those are loading dependent such TAPSE and others less loading dependent such IVA suggest that those improvements could be independent from loading conditions. BACKGROUND Right ventricular dysfunction (RVdisf) is predictor of poor outcome in patients with heart failure and valvular disease. The aim of this study was to evaluate the impact and the evolution of RVdisf in patients with moderate-severe functional mitral regurgitation (FMR) after MitraClip.
METHODS From October 2008 to July 2014, 60 consecutive high surgical risk patients were treated and stratified into two groups: RVdysf-group (TAPSE <16 mm and/or S'TDS <10 cm/sec, 21 patients) and No-RVdysf-group (38 patients).
RESULTS
The overall mean age was 73AE8 (83% male). Ischemic FMR etiology was present in 67%. Mean LVEF was 30AE10. Between the two groups the only significant differences was in presence of stroke, ICD and use of aldosterone-antagonist higher in RVdysf group. Acute procedural success was achieved in 90%. At 6-month echocardiographic follow-up significant improvement of RV function was observed in all patients and was driven by only the results of patients with RVdysf (TAPSE 15AE3.0 vs. 19AE4.5, p¼0.007; S' TDI 7AE1.2 vs. 11AE2.8, p<0.0001; baseline vs. 6-month, respectively). Overall mean follow-up was 565AE310 days. Mean improvement in 6-MWT was 116 m (significant in both groups).
CONCLUSIONS This observational study shows that patients with RVdysf and FMR have significant improvement of RV function after MitraClip procedure. The presence of RVdysf was not predictor of unfavorable clinical outcome.
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